In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on RedHill Biopharma (NASDAQ: RDHL), with a price target of $36. The company’s shares closed yesterday at $8.22.
Ramakanth noted:
“We are maintaining our Buy rating on RedHill and our 12-month price target of $36.00 per ADS based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and 2) price-earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%. 1) commercial; 2) regulatory; 3) clinical; 4) partnership; 5) financial; and 6) intellectual property.”
According to TipRanks.com, Ramakanth is a 2-star analyst with an average return of 0.6% and a 34.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
RedHill Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $36.
See today’s analyst top recommended stocks >>
Based on RedHill Biopharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $10.87 million. In comparison, last year the company had a GAAP net loss of $16.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill’s pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs.
